Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer (Q64395918)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer |
clinical trial |
Statements
A Phase 2 Study of MLN0128 (TAK-228) in Patients With Advanced Non-Small Cell Lung Cancers Harboring NFE2L2 and KEAP1 Mutations (English)
0 references
6 October 2016
0 references
1 December 2019
0 references
30
0 references
18 year
0 references